Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
MSD’s Anti-MRSA Drug Cubicin Filed for Pediatric Use
MSD said on January 27 that it has filed an application seeking Japanese regulatory approval for the pediatric use of Cubicin (daptomycin), a drug to treat infections with methicillin-resistant Staphylococcus aureus (MRSA).The drug is currently approved in Japan for the…
To read the full story
BUSINESS
- Personal iPSC Service to Launch with Production Cost in the 10-Million-Yen Range
March 17, 2026
- Olumiant Gains Oral Suspension Formulation in Japan
March 17, 2026
- BMS Japan “On Track” to Double Sales by 2032 as Launch Wave Nears
March 17, 2026
- Hisamitsu Sets April 17 Shareholders Meeting to Approve Squeeze-Out
March 16, 2026
- AbbVie Japan Files Rinvoq for Vitiligo
March 16, 2026
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…